A Multifunctional Nanodrug Co-Delivering VEGF-siRNA and Dexamethasone for Synergistic Therapy in Ocular Neovascular Diseases

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Nov 28

PMID 39606561

Authors

Xiaochen Ma

Yubo Cui

Min Zhang

Qinghua Lyu

Jun Zhao

Affiliations

Soon will be listed here.

Abstract

Introduction: Oxidant stress, abnormal angiogenesis, and inflammation are three key factors contributing to the development of ocular neovascular diseases (ONDs). This study aims to develop a multifunctional nanodrug, DEX@MPDA-Arg@Si (DMAS), which integrates mesoporous polydopamine, vascular endothelial growth factor (VEGF)-siRNA, and dexamethasone (DEX) to address these therapeutic targets.

Methods: Physicochemical properties of DMAS were measured using transmission electron microscopy and a nanoparticle size analyzer. The encapsulation efficiency and drug loading capacity of DMAS were measured using a UV-visible spectrophotometer. The in vivo therapeutic efficacy and ocular safety of DMAS were evaluated using three established mouse models, including the alkali burn-induced corneal neovascularization (CoNV) model, the oxygen-induced retinopathy (OIR) model, and the laser-induced choroidal neovascularization (CNV) model.

Results: The DMAS nanoparticles demonstrated a uniform bowl-like shape with an average size of 264.9 ± 2.5 nm and a zeta potential of -28.2 ± 4.2 mV. They exhibited high drug-loading efficiency (36.04 ± 3.60% for DEX) and excellent biocompatibility. In vitro studies confirmed its potent antioxidant, anti-inflammatory, and anti-apoptotic properties. In vivo, DMAS treatment led to significant therapeutic effects across all models. It effectively inhibited CoNV, promoted corneal repair, and modulated inflammation in the alkali burn model. In the OIR model, DMAS reduced retinal neovascularization by decreasing VEGF expression. In the laser-induced CNV model, it significantly reduced the CNV area and lesion thickness.

Conclusion: This research developed a multifunctional nanodrug, DMAS, capable of co-delivering VEGF-siRNA and DEX, offering synergistic therapeutic benefits for treating ONDs. The DMAS nanodrug demonstrates promising anti-inflammatory, antioxidative, and anti-angiogenic effects, highlighting its potential as a versatile and effective treatment for multiple ocular conditions.

References

Lyu Q, Hsueh N, Chai C . The Chemistry of Bioinspired Catechol(amine)-Based Coatings. ACS Biomater Sci Eng. 2021; 5(6):2708-2724. DOI: 10.1021/acsbiomaterials.9b00281. View

Carmeliet P, Jain R . Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011; 473(7347):298-307. PMC: 4049445. DOI: 10.1038/nature10144. View

Jonas J, Libondi T, Golubkina L, Spandau U, Schlichtenbrede F, Rensch F . Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol. 2009; 88(6):630-4. DOI: 10.1111/j.1755-3768.2008.01502.x. View

Zhang M, Bahal R, Rasmussen T, Manautou J, Zhong X . The growth of siRNA-based therapeutics: Updated clinical studies. Biochem Pharmacol. 2021; 189:114432. PMC: 8187268. DOI: 10.1016/j.bcp.2021.114432. View

Jin A, Wang Y, Lin K, Jiang L . Nanoparticles modified by polydopamine: Working as "drug" carriers. Bioact Mater. 2020; 5(3):522-541. PMC: 7170807. DOI: 10.1016/j.bioactmat.2020.04.003. View

Mishra N, Kant R, Kandhari K, Tewari-Singh N, Anantharam P, Croutch C . Establishing a Dexamethasone Treatment Regimen To Alleviate Sulfur Mustard-Induced Corneal Injuries in a Rabbit Model. J Pharmacol Exp Ther. 2023; 388(2):469-483. PMC: 10801779. DOI: 10.1124/jpet.123.001680. View

Campochiaro P . Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res. 2015; 49:67-81. PMC: 4651818. DOI: 10.1016/j.preteyeres.2015.06.002. View

Sardoiwala M, Nagpal S, Bhatt B, Roy Choudhury S, Karmakar S . Improved Melatonin Delivery by a Size-Controlled Polydopamine Nanoformulation Attenuates Preclinical Diabetic Retinopathy. Mol Pharm. 2023; 20(6):2899-2910. DOI: 10.1021/acs.molpharmaceut.2c01039. View

Wu M, Hong C, Shen C, Xie D, Chen T, Wu A . Polydopamine nanomaterials and their potential applications in the treatment of autoimmune diseases. Drug Deliv. 2023; 30(1):2289846. PMC: 10987051. DOI: 10.1080/10717544.2023.2289846. View

10.

Yin Q, Han H, Shi K, Zhou J, Zheng S, Yao K . Targeted dexamethasone nano-prodrug for corneal neovascularization management. Biomed J. 2023; 47(1):100592. PMC: 10826162. DOI: 10.1016/j.bj.2023.03.005. View

11.

Wu Y, Li X, Fu X, Huang X, Zhang S, Zhao N . Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases. Adv Sci (Weinh). 2024; 11(32):e2403399. PMC: 11348104. DOI: 10.1002/advs.202403399. View

12.

Zhang J, Jiao J, Niu M, Gao X, Zhang G, Yu H . Ten Years of Knowledge of Nano-Carrier Based Drug Delivery Systems in Ophthalmology: Current Evidence, Challenges, and Future Prospective. Int J Nanomedicine. 2021; 16:6497-6530. PMC: 8473849. DOI: 10.2147/IJN.S329831. View

13.

Zheng D, Huang C, Zhu X, Huang H, Xu C . Performance of Polydopamine Complex and Mechanisms in Wound Healing. Int J Mol Sci. 2021; 22(19). PMC: 8508909. DOI: 10.3390/ijms221910563. View

14.

Tao T, Yang S, He D, Li Z, Chen B, Zhu L . Intravitreal dexamethasone implants facilitate the management of refractory Behçet's uveitis with vasculitis. Clin Immunol. 2023; 251:109633. DOI: 10.1016/j.clim.2023.109633. View

15.

Friedrich M, Aigner A . Therapeutic siRNA: State-of-the-Art and Future Perspectives. BioDrugs. 2022; 36(5):549-571. PMC: 9396607. DOI: 10.1007/s40259-022-00549-3. View

16.

Couch S, Bakri S . Review of combination therapies for neovascular age-related macular degeneration. Semin Ophthalmol. 2011; 26(3):114-20. DOI: 10.3109/08820538.2011.577130. View

17.

Liu A, Liang C, Liu J, Huang Y, Wang M, Wang L . Reactive Oxygen Species─Responsive Lipid Nanoparticles for Effective RNAi and Corneal Neovascularization Therapy. ACS Appl Mater Interfaces. 2022; 14(15):17022-17031. DOI: 10.1021/acsami.1c23412. View

18.

Perez-Gutierrez L, Ferrara N . Biology and therapeutic targeting of vascular endothelial growth factor A. Nat Rev Mol Cell Biol. 2023; 24(11):816-834. DOI: 10.1038/s41580-023-00631-w. View

19.

Cassado A . F4/80 as a Major Macrophage Marker: The Case of the Peritoneum and Spleen. Results Probl Cell Differ. 2017; 62:161-179. DOI: 10.1007/978-3-319-54090-0_7. View

20.

Jiang Y, Wang C, Zu C, Rong X, Yu Q, Jiang J . Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects. Int J Nanomedicine. 2024; 19:9459-9486. PMC: 11456300. DOI: 10.2147/IJN.S466396. View